Ann: Race investor briefing & updated presentation, page-324

perhaps it might be more fruitful to think up some great questions….

Here's one:

Zantrene seems to work best in very low doses over lots of days. it also seems to work best in combination with other drugs.

But, Zantrene, at the moment, must be administered by central line, which is the most unfriendly method of administration of all. I read where you can't keep the central line open for too many days as it can lead to infection. maybe the top number of days is 14?

so, bottom line is that, in the lab, Zantrene is a wonder drug. in the clinic, its method of delivery seriously gets in the way of it b
eing allowed to be a wonder drug.

So, Zantrene urgently needs to be reformulated into an intravenous-delivery drug, or better still, an oral drug.

Race want to raise money to do this, but how easy is it to actually do this? how long does it take? What trials need to be done to prove that the new formulations are valid and safe to include in human trials?

Bottom line question: is solving this drug reformulation project a piece of cake or pie in the sky? can it be done in months or years?